New Protocl: Trifluridine-Tipiracil and Bevacizumab in Metastatic Colorectal Cancer
Study
Phase III, randomized, open-label trial (SUNLIGHT)
|
Adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer
|
Trifluridine–tipiracil (FTD–TPI) + Bevacizumab q28 (n=246) vs. Trifluridine–tipiracil (FTD–TPI) (n=246)
|
|
Efficacy
mOS: 10.8 vs. 7.5 mos, p<0.001
|
12-month OS: 43% vs.30%
|
mPFS: 5.6 vs 2.4 mos, p<0.001
|
12-month PFS: 16% vs. 1%
|
Safety
Grade≥3 AEs: nNutropenia (43.1% vs. 32.1%), Anemia (6.1% vs. 11.0%), hypertension (5.7% vs 1.2%)
|
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
Reviewed by Elvin Chalabiyev, MD on May 20, 2023
